Association between statin use and longitudinal changes in skeletal muscle mass: A population-based cohort study
- 1Department of Rehabilitation Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Republic of Korea
- 2Department of Family Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Republic of Korea
Abstract
Statins are widely prescribed for cardiovascular risk reduction, yet concerns remain regarding their effects on skeletal muscle. Evidence on the longitudinal relationship between statin use and muscle mass remains inconsistent, particularly in population-based settings. Therefore, this study investigated the longitudinal association between statin use and changes in total and region-specific skeletal muscle mass in a population-based adult cohort. This single-center retrospective cohort study analyzed adults with repeated health examinations from 2021 to 2023. Skeletal muscle mass was assessed using bioelectrical impedance analysis, including upper limb lean mass (ULM), lower limb lean mass (LLM), appendicular lean mass (ALM), and skeletal muscle index (SMI). Statin use was determined from medical records and self-reported medication histories. Linear mixed-effects models with random intercepts helped evaluate longitudinal changes in muscle mass according to statin use. Models were sequentially adjusted for age and sex, and further for body mass index and diabetes mellitus. Among 2,300 participants, 334 (14.5%) were continuous statin users, who were older and had a higher prevalence of metabolic comorbidities than non-users. In unadjusted analyses, statin users exhibited significantly greater declines in LLM and ALM than non-users. These differences remained significant after adjustment for age and sex. However, after further adjustment for body mass index and diabetes mellitus, associations between statin use and changes in all muscle mass indices were no longer significant. No significant differences were observed for ULM or SMI in any model. In this longitudinal cohort, statin use was not independently associated with accelerated skeletal muscle mass decline after adjustment for key metabolic confounders. These findings suggest that underlying metabolic and clinical characteristics, rather than statin exposure, may play a more important role in longitudinal muscle mass changes.
Related
- Longitudinal Association Between the Change in Serum Procollagen Type III N-Terminal Peptide (PIIINP) and Skeletal Muscle Loss in Patients with Gastrointestinal Cancer Receiving Chemotherapy: A Prospective Cohort Study
- Health information sources and behaviour changes in a community population: a longitudinal study
- Association between dental checkup frequency and longitudinal changes in total healthcare expenditures: a longitudinal cohort study
- Moderating effect of social support on the association between changes in financial stress and depressive and anxiety symptoms during the COVID-19 pandemic in Medicaid recipients: a longitudinal study
- Longitudinal Changes in Structural and Functional Brain Imaging and Their Association with Cognitive and Neuropsychiatric Symptoms in Hashimoto Encephalopathy with Anti-NAE Antibody
BibTeX
@article{lee2026association,
title = {{Association between statin use and longitudinal changes in skeletal muscle mass: A population-based cohort study}},
author = {Jiye Lee and Suho Jun and Jun-Hyuk Lee and Jee Hye Han and Hyun Jung Kim},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0355202},
url = {https://doi.org/10.1371/journal.pone.0355202},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Association between statin use and longitudinal changes in skeletal muscle mass: A population-based cohort study
AU - Jiye Lee
AU - Suho Jun
AU - Jun-Hyuk Lee
AU - Jee Hye Han
AU - Hyun Jung Kim
PY - 2026
DA - 2026/09/03
JO - PLOS One
DO - 10.1371/journal.pone.0355202
UR - https://doi.org/10.1371/journal.pone.0355202
AB - Statins are widely prescribed for cardiovascular risk reduction, yet concerns remain regarding their effects on skeletal muscle. Evidence on the longitudinal relationship between statin use and muscle mass remains inconsistent, particularly in population-based settings. Therefore, this study investigated the longitudinal association between statin use and changes in total and region-specific skeletal muscle mass in a population-based adult cohort. This single-center retrospective cohort study analyzed adults with repeated health examinations from 2021 to 2023. Skeletal muscle mass was assessed using bioelectrical impedance analysis, including upper limb lean mass (ULM), lower limb lean mass (LLM), appendicular lean mass (ALM), and skeletal muscle index (SMI). Statin use was determined from medical records and self-reported medication histories. Linear mixed-effects models with random intercepts helped evaluate longitudinal changes in muscle mass according to statin use. Models were sequentially adjusted for age and sex, and further for body mass index and diabetes mellitus. Among 2,300 participants, 334 (14.5%) were continuous statin users, who were older and had a higher prevalence of metabolic comorbidities than non-users. In unadjusted analyses, statin users exhibited significantly greater declines in LLM and ALM than non-users. These differences remained significant after adjustment for age and sex. However, after further adjustment for body mass index and diabetes mellitus, associations between statin use and changes in all muscle mass indices were no longer significant. No significant differences were observed for ULM or SMI in any model. In this longitudinal cohort, statin use was not independently associated with accelerated skeletal muscle mass decline after adjustment for key metabolic confounders. These findings suggest that underlying metabolic and clinical characteristics, rather than statin exposure, may play a more important role in longitudinal muscle mass changes.
SN - 1932-6203
ER -